ArticleDiscover oncology2025
Preliminary study on SIRI dynamic changes for the efficacy prediction and prognosis evaluation of advanced cancer patients treated with immunotherapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo investigate the values of systemic inflammatory response index (SIRI) and its dynamic changes in predicting the efficacy and evaluating the prognosis of immunotherapy for advanced cancers.
methodsA retrospective analysis was conducted on the clinical data of 245 patients with locally advanced and advanced cancers who received immune checkpoint inhibitors (ICI) treatment at the 940 Hospital of the Joint Logistics Support Force from June 2020 to June 2023.The χ2-test was used to compare the clinical pathological characteristics of patients in the disease control group and the no-control group, and Kruskal-Wallis test was used to compare the differences in SIRI pre-treatment, disease remission, and disease progression. The correlation between SIRI and progression free survival (PFS) of patients was analyzed using Kaplan-Meier survival curve and Log-rank test; and factors affecting PFS in cancer patients receiving ICIs treatment were analyzed through univariate and multivariate COX regression analysis.
resultsThere was a significant difference in the number of treatment lines between the disease control group and no-control group (P = 0.042), but no significant differences were observed in gender, age, tumor differentiation, number of metastatic organs and treatment plan between the two groups (P > 0.05). Compared with pre-treatment, the SIRI decreased during disease remission and increased again during disease progressed. Kaplan- Meier survival curves indicated that patients with high SIRI had shorter PFS than those with low SIRI (P = 0.019, < 0.001, 0.012). Univariate and multivariate COX regression analysis revealed that pre-treatment high SIRI (HR = 2.804,95%CI 1.150 ~ 6.838, P = 0.023) and disease remission high SIRI (HR = 2.469,95%CI 1.513 ~ 4.029, P<0.001) were independent risk factors for PFS in cancer patients undergoing immunotherapy.
conclusionThe inflammatory index SIRI can be a dynamic biomarker for evaluating the efficacy and prognosis of advanced cancer patients receiving ICI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.